Italy’s Angelini pens $360M biobucks pact for Cureverse’s phase 1 brain disorder drug 21.10.2024 16:30 Fiercebiotech.com Italy’s Angelini pens $360M biobucks pact for Cureverse’s phase 1 brain disorder drug jwaldron Mon, 10/21/2024 - 09:30
